Session 1: Respiratory Vaccines

1. Identify the high-risk groups that may lead patients to experience poorer outcomes from respiratory illness, including older age, immune status and other comorbidities. (Health Advocate)

2. Review considerations for stratifying a patient’s level of individual risk by utilizing a case-study based approach. (Collaborator)

3. Select an appropriate fall respiratory vaccination strategy based on current NACI guidance and supporting clinical evidence. (Family Medicine Expert)

​

Session 2: Travel Health

1. Determine the importance of travel health discussions in adults and those with chronic health conditions. (Communicator)

2. Discuss strategies to reduce the risk of common travel-related conditions in people travelling to resort destinations in the Caribbean. (Health Advocate)

3. Review recommendations you can make in practice tomorrow to improve travel health in your patients. (Family Medicine Expert)

​

Session 3: Asthma

1. Recognize the urgency and unmet need for better asthma control. (Health Advocate)

2. Apply ideal disease control during patient encounters to improve outcomes for patients with asthma.  (Family Medicine Expert)

3. Understand the advantages of triple versus dual agents and when each should be utilized according to new and emerging literature. (Scholar)

​

Session 4: Dyslipidemia

1. Identify new guideline recommended tests that primary care providers can apply to assist with CV risk stratification, such as testing for Lp(a) and coronary artery calcium. (Scholar)

2. Describe the CCS dyslipidemia guideline recommendations for initiation and intensification of therapy. (Family Medicine Expert)

3. Recognize important considerations for intensification of therapy in dyslipidemia management. (Family Medicine Expert)

​

Session 5: Insomnia

1. Review the assessment and diagnosis of insomnia. (Scholar)

2. Recognize key considerations in the pharmacological management of insomnia. (Family Medicine Expert)

3. Discuss the role of orexins in sleep-wake regulation, and describe the use of the orexin receptor antagonist class in insomnia treatment. (Family Medicine Expert)

​

Session 5: Chronic Kidney Disease (CKD)

1. Define diabetic kidney disease (DKD). (Communicator)

2. Recognize opportunities for treatment adjustment or intensification for patients with CKD with or without T2D. (Family Medicine Expert)

3. Implement guideline-based outcome reducing treatments in patients with T2DM and CKD. (Scholar)

​

Session 7: Major Depressive Disorder (MDD)

1. Understand the importance of using measurement-based care to provide guideline-based care in MDD. (Scholar)

2. Recognize the early predictors of response and remission in MDD, and the importance of early optimized treatment. (Family Medicine Expert)

​

Session 8: Nonalcoholic steatohepatitis (NASH)

1. Describe the pathophysiology and burden of disease with NASH. (Communicator)

2. Identify who to screen, when and how to diagnose NASH in primary care. (Family Medicine Expert)

3. Develop treatment approaches and care pathways for NASH. (Leader).

​

Session 9: Acne

1. Describe the pathophysiology of acne and the characteristics that differentiate it from acne mimickers. (Communicator)

2. Review treatment options of acne (focusing on topical retinoids) and realize why the choice of vehicle is an important consideration in acne therapy. (Family Medicine Expert)

3. Develop patient counselling and strategies to improve adherence and patient outcomes. (Leader)